No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Whan In Pharm Co.,Ltd. is a South Korean pharmaceutical enterprise specializing in the research, development, manufacturing, promotion, and distribution of therapeutic products. Their comprehensive portfolio encompasses treatments for mental health conditions (such as antidepressants and antipsychotics), neurological disorders (including nootropics, anti-dementia, and anti-epileptics), cardiovascular and gastrointestinal ailments, infectious diseases, allergies, pain and inflammation, metabolic imbalances, respiratory issues, and a variety of other central nervous system applications. Established in 1978, the company's corporate headquarters are situated in Seoul, South Korea.
www.whanin.comNo one on the platform currently holds 016580.KS.
No tracked institution reports a position in 016580.KS as of their last filing.
No one on the platform has traded 016580.KS yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 3.3% | 7.1% | 8.0% | — | — | — |
| Rev. Growth % | -1.7% | 8.2% | ||||
| Profit Margin % | 5.3% | 10.9% | 12.4% | |||
| Free Cash Flow Margin % | 2.4% | -2.6% | 2.9% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $283.3B | +10.5% | $1253.00 | $1253.00–$1253.00 | — | 1 |
| 2027 | $311.2B | +9.8% | $1428.00 | $1428.00–$1428.00 | — | 1 |
| 2028 | $340.4B | +9.4% | $1617.00 | $1617.00–$1617.00 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| $9120.00 |
| -0.76% |
| $118.5B |
| — |
| 002620.KSJeil Pharma Holdings Inc | $7400.00 | -1.20% | $113.6B | — |
| 003120.KSIlsung Is Co., Ltd. | $22250.00 | +0.68% | $159.4B | — |
Source: Financial Modeling Prep · peers by sector/industry